FDA Approves Unknown Drug — RADIOMEDIX

# FDA Approves Radiopharmaceutical Generic from Radiomedix The FDA approved Radiomedix's generic radiopharmaceutical application (ANDA216410) on June 8, 2026, positioning the company to capture market share in the growing nuclear medicine segment and potentially lowering treatment costs for patients requiring diagnostic or therapeutic nuclear imaging. This approval strengthens Radiomedix's portfolio in the specialized radiopharmaceutical market, where supply constraints and high costs have historically limited patient access.